Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Chęć udziału w badaniu potwierdzona pisemną zgodą
- •Ogólny stan zdrowia oceniony jako dobry lub umiarkowany (skala ECOG 0-2)
- •Prawidłowe funkcjonowanie wątroby, nerek, układu krzepnięcia i trzustki
- •Potwierdzona diagnoza jednego z typów chłoniaka lub białaczki (MCL lub CLL/SLL w fazie 2)
- •Zastosowanie niezawodnej antykoncepcji podczas badania i 90 dni po ostatniej dawce leku
✗ Disqualifies
- •Inny nowotwór w ciągu ostatnich 2 lat (poza białaczką leczoną w tym badaniu)
- •Trwające leczenie innego nowotworu lub przyjmowanie sterydów
- •Przyjmowanie leków, które wpływają na metabolizm leku badanego (w ostatnich 2 tygodniach)
- •Zaangażowanie mózgu i opon mózgowych w proces choroby
- •Przeszczep szpiku kostnego, terapia komórkami CAR-T lub przeszczep od dawcy w ostatnich 3-6 miesiącach
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (29)
The First Affiliated Hospital of Bengbu Medical University
Bengbu, China
Anhui Provincial Hospital
Hefei, China
Peking University Third Hospital
Beijing, China
Beijing Chao Yang Hospital,Capital Medical University
Beijing, China
Second Affiliated Hospital of Army Medical University (Xinqiao Hospital)
Chongqing, China
Fujian Medical University Union Hospital
Fuzhou, China
Sun Yat Sen University Cancer Center
Guangzhou, China
Guangdong Provincial Peoples Hospital Huifu Branch
Guangzhou, China
The Peoples Hospital of Guangxi Zhuang Autonomous Region
Nanning, China
Nanyang Central Hospital
Nanyang, China
Henan Cancer Hospital
Zhengzhou, China
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Xiangyang Central Hospital
Xiangyang, China
The Second Xiangya Hospital of Central South University
Changsha, China
Jiangsu Province Hospital
Nanjing, China
The First Affiliated Hospital of Soochow University
Suzhou, China
The First Affiliated Hospital of Nanchang University Branch Donghu
Nanchang, China
Jiangxi Province Cancer Hospital
Nanchang, China
The First Hospital of Jilin University
Changchun, China
Affiliated Zhongshan Hospital of Dalian University
Dalian, China
Shandong Cancer Hospital
Jinan, China
Qingdao Central Hospital
Qingdao, China
Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
Shanghai, China
Shanxi Provincial Cancer Hospital
Taiyuan, China
West China Hospital, Sichuan University
Chengdu, China
Institute of Hematology and Hospital of Blood Disease
Tianjin, China
First Affiliated Hospital of Kunming Medical University
Kunming, China
The First Affiliated Hospital, Zhejiang University School of Medicine Branch Yuhang
Hangzhou, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
Trial contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.